FDMT in the 13F filings
4D Molecular Therapeutics In · CUSIP 35104E100
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 26
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 0 listed it in both
- Shares listed
- 9,019,879
- combined, among listed positions
- Reported value
- $68m
- combined, at the quarter end
Among the 92 comparable managers: 16 buyers (opened or added shares) and 10 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +3,739,389.
Managers listing FDMT in Q4 2025
26 of 26 holders
Largest increases and reductions, by shares
Increases
- Janus Henderson Group Ltdexisting position · 4,635,875 shares now+2,882,508
- Point72 Asset Management LPnew position · 1,539,860 shares now+1,539,860
- Woodline Partners LPnew position · 200,001 shares now+200,001
- Renaissance Technologies LLCexisting position · 512,900 shares now+199,714
- Jane Street Group LLCexisting position · 224,903 shares now+107,988
Reductions
- Millennium Management LLCexisting position · 96,364 shares now-1,053,037
- Two Sigma Advisers LPexisting position · 275,300 shares now-274,400
- Marshall Wace LLPexisting position · 27,758 shares now-118,149
- Acadian Asset Management LLCexisting position · 30,131 shares now-24,970
- Schonfeld Strategic Advisors LLCexisting position · 161,982 shares now-17,093
New positions and exits
New (5)
Exited (1)
- Brevan Howard Capital Management LPwas $143k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2020 | 4 | $172m | n.a. | n.a. |
| Q1 2021 | 2 | $175m | n.a. | n.a. |
| Q2 2021 | 2 | $96m | n.a. | n.a. |
| Q3 2021 | 2 | $109m | n.a. | n.a. |
| Q4 2021 | 2 | $89m | n.a. | n.a. |
| Q1 2022 | 1 | $60m | n.a. | n.a. |
| Q2 2022 | 1 | $27m | n.a. | n.a. |
| Q3 2022 | 1 | $32m | n.a. | n.a. |
| Q4 2022 | 3 | $120m | n.a. | n.a. |
| Q1 2023 | 2 | $100m | n.a. | n.a. |
| Q2 2023 | 2 | $138m | n.a. | n.a. |
| Q3 2023 | 2 | $96m | n.a. | n.a. |
| Q4 2023 | 2 | $160m | 1 | 0 |
| Q1 2024 | 5 | $211m | 4 | 1 |
| Q2 2024 | 3 | $130m | 0 | 3 |
| Q3 2024 | 1 | $34m | 0 | 2 |
| Q4 2025 | 1 | $35m | 16 | 10 |
| Q1 2026 | 1 | $49m | 8 | 15 |
| Q2 2026 | 1 | $76m | 14 | 6 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
FDMT and GILD →FDMT and AMGN →FDMT and ARGX →Choose a stock to compare with FDMT →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own FDMT, latest filings →Back to the 13F Explorer →